Phase 3 Study of Navitoclax in Myelofibrosis

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis

Disease Types: Hematology

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For more information:

https://clinicaltrials.gov/ct2/show/NCT04472598?term=TRANSFORM-1&draw=2&rank=1